Fig. 1 · Structure

Documents & Downloads

Trametinib (GSK1120212, JTP-74057)

Cat. No. A11029 CAS 871700-17-3

MEK Inhibitor

Trametinib (GSK1120212, JTP-74057) strongly prevented the activities of MEK1 and MEK2 kinases rather than activities of other 98 kinases.

In Stock

Publications for Trametinib

18 publications citing this product

  1. UyenPhuong Tran, .et al. , J Nat Prod, 2025, Nov 28;88(11):2789-2794 PMID: 41124592
  2. Khanh Nguyen, .et al. , Sci Rep, 2025, Oct 22;15(1):36926 PMID: 41125616
  3. Yue Zhou, .et al. , Biol Pharm Bull, 2025, 48(7):1089-1095 PMID: 40721370
  4. Song Han, .et al. , Neoplasia, 2025, Jan:59:101070 PMID: 39541736
  5. Majid Momeny, .et al. , EMBO Mol Med, 2024, Jun 17 PMID: 38886591
  6. Meenu Kesarwani, .et al. , Blood Adv, 2024, Jun 11;8(11):2765-2776 PMID: 38531054
  7. Saeko Yoshioka, .et al. , Int J Tryptophan Res, 2022, Nov 30;15 PMID: 36467776
  8. Tsung-Ming Chang, .et al. , Journal of Biomedical Science, 2022, 29:92 PMID: 36336681
  9. Nao Yamagishi, .et al. , Biol Pharm Bull, 2022, 45(10):1553-1558 PMID: 36184515
  10. Hayato Mizuta, .et al. , Nat Commun, 2021, Feb 24;12(1):1261 PMID: 33627640

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Trametinib (JTP-74057) showed ATP-noncompetitive MEK inhibition. Potency depended on assay design: coupled B-Raf/u-MEK1 and u-MEK2 assays gave IC50 values of 3.5 and 5.3 nM, whereas preactivated MEK1 and MEK2 assays gave 290 and 190 nM. Direct Raf/MBP assays gave IC50 values >10,000 nM. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
MEK1 (Cell-free assay) 0.92 nM
MEK2 (Cell-free assay) 1.8 nM

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 0.46 μM Antiproliferative activity against human A549 cells harboring KRAS G12S mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay [PMID: 32305784]
DLD-1 IC50 1.34 μM Anticancer activity against human DLD-1 cells assessed as reduction in cell viability incubated for 24 hrs by Cell Titer-Glo assay [PMID: 33445154]
HCT-116 IC50 0.019 μM Antiproliferative activity against human HCT116 cells harboring KRAS G13D mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay [PMID: 32305784]
HCT-116 IC50 1.16 μM Anticancer activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by Cell Titer-Glo assay [PMID: 33445154]
HL-60 IC50 0.003 μM Antiproliferative activity against human HL60 cells harboring NRAS K61L mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay [PMID: 32305784]
MDA-MB-231 IC50 0.018 μM Antiproliferative activity against human MDA-MB-231 cells harboring KRAS G13D/BRAF G464V mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay [PMID: 32305784]
MDA-MB-231 GI50 25 nM Growth inhibition of human MDA-MB-231 cells after 3 days by DAPI staining 10.1039/C3MD00290J

Trametinib (GSK1120212, JTP-74057) Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Trametinib (GSK1120212, JTP-74057) from 3 published references. In vitro models include recombinant Raf–MEK–ERK and preactivated MEK–ERK kinase assays; HT-29 colorectal and ACHN kidney cancer cells.

Trametinib (GSK1120212, JTP-74057) In Vitro Studies

In 24-hour HT-29 and ACHN experiments, trametinib inhibited ERK phosphorylation. Reduced MEK phosphorylation was apparent in HT-29; low basal phospho-MEK limited assessment of a decrease in ACHN. [1]

In engineered 293-ErbB2/3 cells, trametinib blocked TPA-induced ERK and ErbB2 Thr-677 phosphorylation and prevented feedback downregulation of ErbB2/ErbB3 tyrosine phosphorylation. The result illustrates how MEK inhibition can release receptor feedback in a defined signaling model. [2]

MEK inhibition depends on assay activation state

Biochemical assay · Recombinant Raf–MEK–ERK and preactivated MEK–ERK kinase assays [1]

JTP-74057 inhibited the coupled activation cascade more potently than preactivated MEK; direct Raf/MBP assays were negative. ATP-varied kinetics supported ATP-noncompetitive allosteric inhibition.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Preactivated p-MEK1 phosphorylating ERK2IC50 290 nM; PD0325901: 110 nM[1]
Preactivated p-MEK2 phosphorylating ERK2IC50 190 nM; PD0325901: 140 nM[1]
B-Raf V600E/u-MEK1 and B-Raf V600E/u-MEK2 coupled ERK2 phosphorylationIC50 3.5 nM (MEK1); 5.3 nM (MEK2); PD0325901: 4.1 and 3.6 nM, respectively[1]
Truncated c-Raf/u-MEK1 and c-Raf/u-MEK2 coupled ERK2 phosphorylationIC50 11 nM (MEK1); 7.9 nM (MEK2); PD0325901: 24 and 6.0 nM, respectively[1]
B-Raf and c-Raf phosphorylation of MBPIC50 >10,000 nM for both Raf isoforms; PD0325901 also >10,000 nM[1]
ATP-varied MEK–ERK kineticsqualitative ATP-noncompetitive allosteric inhibition[1]

Literature-Reported Treatment Conditions

Treatment concentration
IC50 concentration-response series; Fig 2D JTP-74057: 0, 0.125, 0.25 or 0.5 μM
Exposure duration
15-min preincubation without ATP, then 20-min kinase reaction at 30°C
Method
Recombinant kinase assays; 10 μM ATP for Table 1 assays; ATP varied in Fig 2D
Co-treatment
PD0325901 and U0126 were separate comparator treatments.
Reported limits
Full IC50 titration range and solvent concentration not specified in the read kinase-assay methods. Coupled-assay IC50 is not a binding constant or treatment dose.
Methods and source locations

Compound reported in the paper: Trametinib; Compound label in the paper: JTP-74057

Evidence concerns the reported trametinib material. Solvate/salt equivalence and Adooq lot performance were not established.

Table 1, enzyme rows; Figure 2D and caption; Results Effects of JTP-74057 on enzyme activity; Methods Enzymatic kinase assays

Preactivated p-MEK1 phosphorylating ERK2: Radiolabeled ATP incorporation; ERK2 substrate or MBP direct-Raf control. Means of three independent experiments; no dispersion given in table. — Table 1; enzyme rows; means of three independent experiments

Preactivated p-MEK2 phosphorylating ERK2: Radiolabeled ATP incorporation; ERK2 substrate or MBP direct-Raf control. Means of three independent experiments; no dispersion given in table. — Table 1; enzyme rows; means of three independent experiments

B-Raf V600E/u-MEK1 and B-Raf V600E/u-MEK2 coupled ERK2 phosphorylation: Radiolabeled ATP incorporation; ERK2 substrate or MBP direct-Raf control. Means of three independent experiments; no dispersion given in table. — Table 1; enzyme rows; means of three independent experiments

Truncated c-Raf/u-MEK1 and c-Raf/u-MEK2 coupled ERK2 phosphorylation: Radiolabeled ATP incorporation; ERK2 substrate or MBP direct-Raf control. Means of three independent experiments; no dispersion given in table. — Table 1; enzyme rows; means of three independent experiments

B-Raf and c-Raf phosphorylation of MBP: Radiolabeled ATP incorporation; ERK2 substrate or MBP direct-Raf control. Means of three independent experiments; no dispersion given in table. — Table 1; enzyme rows; means of three independent experiments

ATP-varied MEK–ERK kinetics: Double-reciprocal analysis; no-inhibitor and PD0325901/U0126 comparator series; caption specifies means of two or three independent experiments. — Figure 2D/caption; Results Effects of JTP-74057 on enzyme activity

Cell-dependent MEK and ERK phosphorylation responses

Cell-based study · HT-29 colorectal and ACHN kidney cancer cells [1]

After 24 h, trametinib suppressed ERK phosphorylation in both models and reduced detectable phospho-MEK in HT-29. ACHN had low basal phospho-MEK, limiting detection of a decrease; high-dose PD0325901 increased phospho-MEK.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Phosphorylated and total MEK1/2 and ERK1/2qualitative ERK phosphorylation inhibited; phospho-MEK decrease apparent in HT-29, limited by low basal signal in ACHN[1]

Literature-Reported Treatment Conditions

Treatment concentration
0, 0.1, 1, 10, 100, 1000 nM JTP-74057 or PD0325901
Exposure duration
24 h
Method
Cell exposure followed by immunoblotting
Co-treatment
None; PD0325901 tested separately.
Reported limits
Figure 3A replicate count and solvent concentration are not specified in the read caption/methods; qualitative blots, no fitted cellular IC50 extracted.
Methods and source locations

Compound reported in the paper: Trametinib; Compound label in the paper: JTP-74057

Evidence concerns the reported trametinib material. Solvate/salt equivalence and Adooq lot performance were not established.

Figure 3A and caption; Results Alteration of MEK phosphorylation status; Methods cell culture, reagents and Western blot analysis

Phosphorylated and total MEK1/2 and ERK1/2: Western blots; total MEK and ERK controls, zero-compound lanes and separate PD0325901 comparator. — Figure 3A and accompanying Results

MEK blockade interrupts ErbB2/ErbB3 negative feedback

Cell-based study · HEK293 cells stably expressing ErbB2 and ErbB3 (293-ErbB2/3) [2]

Trametinib pretreatment blocked TPA-induced ERK activation and ErbB2 Thr-677 phosphorylation, while preventing the TPA-induced loss of ErbB2/ErbB3 tyrosine phosphorylation. This is a stimulated feedback model, not a tumor-growth assay.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ERK, ErbB2 Thr-677 and ErbB2/ErbB3 tyrosine phosphorylationqualitative TPA-induced phospho-ERK and phospho-Thr-677 blocked; receptor tyrosine-phosphorylation downregulation prevented[2]

Literature-Reported Treatment Conditions

Treatment concentration
Trametinib 0.03 μM
Exposure duration
Pretreatment followed by TPA for 10 min
Method
Cellular immunoblot feedback experiment
Vehicle
DMSO; Materials states final concentration <0.1% for chemical agents.
Co-treatment
TPA stimulation; not an antitumor combination-efficacy claim.
Reported limits
Pretreatment duration and TPA concentration are not specified in Fig 5a caption; 100 ng/ml reported in Fig 1 is not assigned to this experiment. Fig 5f n=5 pertains to mutant quantification, not Fig 5a.
Methods and source locations

Compound reported in the paper: Trametinib; Compound label in the paper: trametinib

Evidence concerns the reported trametinib material. Solvate/salt equivalence and Adooq lot performance were not established.

Figure 5a and caption; Results Thr-677 is a feedback phosphorylation site of ErbB2; Methods Materials and Western blotting

ERK, ErbB2 Thr-677 and ErbB2/ErbB3 tyrosine phosphorylation: Four-condition immunoblot: ±TPA and ±trametinib; total receptor proteins and Actin controls. — Figure 5a; Results Thr-677 is a feedback phosphorylation site

Trametinib (GSK1120212, JTP-74057) In Vivo Studies

In mice bearing canine M5 melanoma xenografts, oral trametinib at 1.5 mg/kg daily showed no significant tumor-size benefit over vehicle (reported P > 0.5). Combination with NVP-BEZ235 inhibited growth more strongly; this combination result cannot be attributed to trametinib alone. [3]

Limited monotherapy activity in canine melanoma xenografts

Animal study · Female nu/nu athymic nude mice, 6–8 weeks old, bearing canine M5 oral-mucosal-melanoma xenografts; randomized at 75–150 mm³ [3]

Trametinib alone did not significantly reduce tumor size versus vehicle. NVP-BEZ235 alone delayed growth, and combined treatment produced greater inhibition. Results are from one concurrent experiment and do not establish human efficacy.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor volume versus vehiclereported P value P > 0.5[3]
Day-10 tumor volume versus vehiclereported P value P = 0.005[3]
Day-10 tumor-growth inhibition, combinationreported P value P < 0.0005[3]

Conditions shared by the study groups

Route
Oral gavage
Treatment course
Up to approximately 35–39 days; five mice/group harvested day 10; remaining ten continued
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Matched vehicles
Drug vehicles only
Concurrent matched drug-vehicle group; 15 mice/group initiallyReference tumor-growth group[3]
Trametinib monotherapy
1.5 mg/kg trametinib
Concurrent matched drug-vehicle group; 15 mice/group initiallyTumor size similar to vehicle (P > 0.5)[3]
NVP-BEZ235 monotherapy
30 mg/kg NVP-BEZ235
Concurrent matched drug-vehicle group; 15 mice/group initiallyDay-10 growth delay versus vehicle (P = 0.005)[3]
Trametinib + NVP-BEZ235
1.5 mg/kg trametinib + 30 mg/kg NVP-BEZ235
Concurrent matched drug-vehicle group; 15 mice/group initiallyGreater growth inhibition; day-10 P < 0.0005 reported[3]
Matched vehicles
Model: Female nu/nu athymic nude mice, 6–8 weeks old, bearing canine M5 oral-mucosal-melanoma xenografts; randomized at 75–150 mm³
Frequency: Matched dosing schedule
Vehicle: 0.5% HPMC/0.2% Tween and NMP/PEG300
Reported limits: One experiment. Fig 5 caption simplifies NVP-BEZ235 frequency to daily; Methods schedule used.
Trametinib monotherapy
Model: Female nu/nu athymic nude mice, 6–8 weeks old, bearing canine M5 oral-mucosal-melanoma xenografts; randomized at 75–150 mm³
Frequency: Daily
Vehicle: 0.5% hydroxypropyl methylcellulose (HPMC)/0.2% Tween
Reported limits: One experiment. Fig 5 caption simplifies NVP-BEZ235 frequency to daily; Methods schedule used.
NVP-BEZ235 monotherapy
Model: Female nu/nu athymic nude mice, 6–8 weeks old, bearing canine M5 oral-mucosal-melanoma xenografts; randomized at 75–150 mm³
Frequency: Five days/week
Vehicle: N-methyl-2-pyrrolidone/polyethylene glycol 300 (NMP/PEG300)
Reported limits: One experiment. Fig 5 caption simplifies NVP-BEZ235 frequency to daily; Methods schedule used.
Trametinib + NVP-BEZ235
Model: Female nu/nu athymic nude mice, 6–8 weeks old, bearing canine M5 oral-mucosal-melanoma xenografts; randomized at 75–150 mm³
Frequency: Trametinib daily; NVP-BEZ235 five days/week
Vehicle: Respective formulations: HPMC/Tween and NMP/PEG300
Reported limits: One experiment. Fig 5 caption simplifies NVP-BEZ235 frequency to daily; Methods schedule used.
Methods and source locations

Compound reported in the paper: Trametinib; Compound label in the paper: GSK1120212 (trametinib)

Evidence concerns the reported trametinib material. Solvate/salt equivalence and Adooq lot performance were not established.

Figure 5A–B and caption; Results Combined inhibitor mediated arrest of solid MM tumor growth; Methods Animal studies and Statistics

Tumor volume versus vehicle: Caliper tumor volumes; no significant monotherapy benefit reported. — Results Combined inhibitor mediated arrest; Figure 5A–B

Day-10 tumor volume versus vehicle: Single-agent NVP-BEZ235 comparator; t test per Statistics. — Figure 5B/caption and Results

Day-10 tumor-growth inhibition, combination: Caption reports significant inhibition; text describes greater inhibition than either single drug. No exact volume inferred from dots. — Figure 5B/caption and Results

Matched vehicles · Figure 5A–B and caption; Results Combined inhibitor mediated arrest of solid MM tumor growth; Methods Animal studies and Statistics

Trametinib monotherapy · Figure 5A–B and caption; Results Combined inhibitor mediated arrest of solid MM tumor growth; Methods Animal studies and Statistics

NVP-BEZ235 monotherapy · Figure 5A–B and caption; Results Combined inhibitor mediated arrest of solid MM tumor growth; Methods Animal studies and Statistics

Trametinib + NVP-BEZ235 · Figure 5A–B and caption; Results Combined inhibitor mediated arrest of solid MM tumor growth; Methods Animal studies and Statistics

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 871700-17-3
Applications MEK Inhibitor
Formula C26H23FIN5O4
Molecular Weight 615.4
Synonyms GSK-1120212; GSK212; JTP-74057
SMILES
CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC(=CC=C4)NC(=O)C)C5CC5

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 19 mg/mL (30.87 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
2 mg/mL
Vehicle
4% DMSO+corn oil

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Trametinib (GSK1120212, JTP-74057) Research References

  1. [1] Takayuki Yoshida, Junya Kakegawa, Takayuki Yamaguchi, et al. Identification and Characterization of a Novel Chemotype MEK Inhibitor Able to Alter the Phosphorylation State of MEK1/2 Oncotarget (2012). PMID: 23237773 DOI: 10.18632/oncotarget.747 Source material
  2. [2] Yuki Kawasaki, Ayaka Sakimura, Chul Min Park, et al. Feedback control of ErbB2 via ERK-mediated phosphorylation of a conserved threonine in the juxtamembrane domain Scientific Reports (2016). PMID: 27531070 DOI: 10.1038/srep31502 Source material
  3. [3] Bih-Rong Wei, Helen T. Michael, Charles H. C. Halsey, et al. Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma Pigment Cell & Melanoma Research (2016). PMID: 27463366 DOI: 10.1111/pcmr.12512 Source material

Publications

18 publications citing this product

  1. UyenPhuong Tran, .et al. , J Nat Prod, 2025, Nov 28;88(11):2789-2794 PMID: 41124592
  2. Khanh Nguyen, .et al. , Sci Rep, 2025, Oct 22;15(1):36926 PMID: 41125616
  3. Yue Zhou, .et al. , Biol Pharm Bull, 2025, 48(7):1089-1095 PMID: 40721370
  4. Song Han, .et al. , Neoplasia, 2025, Jan:59:101070 PMID: 39541736
  5. Majid Momeny, .et al. , EMBO Mol Med, 2024, Jun 17 PMID: 38886591
  6. Meenu Kesarwani, .et al. , Blood Adv, 2024, Jun 11;8(11):2765-2776 PMID: 38531054
  7. Saeko Yoshioka, .et al. , Int J Tryptophan Res, 2022, Nov 30;15 PMID: 36467776
  8. Tsung-Ming Chang, .et al. , Journal of Biomedical Science, 2022, 29:92 PMID: 36336681
  9. Nao Yamagishi, .et al. , Biol Pharm Bull, 2022, 45(10):1553-1558 PMID: 36184515
  10. Hayato Mizuta, .et al. , Nat Commun, 2021, Feb 24;12(1):1261 PMID: 33627640
  11. Keisuke Yanagida, .et al. , Dev Cell, 2020, 52 (6), 779-793 PMID: 32059774
  12. Hamzehlou S, .et al. , Eur J Pharmacol, 2019, Nov 15;863:172705 PMID: 31574259
  13. Kanemaru Y, .et al. , Acta Neuropathol Commun, 2019, Jul 25;7(1):119 PMID: 31345255
  14. Chul Min Park, .et al. , Oncol Lett, 2018, Feb; 15(2): 1758-1762 PMID: 29434871
  15. Sumi T, .et al. , Biochem Biophys Res Commun, 2018, Jun 18;501(1):253-258 PMID: 29727601
  16. Toshiyuki Sumi, .et al. , Int J Oncol, 2018, Jul; 53(1): 33-46 PMID: 29658609
  17. Fujita KI, .et al. , J Pharm Sci, 2017, Sep;106(9):2632-2641 PMID: 28479358
  18. Yuki Kawasaki, .et al. , Sci Rep, 2016, 6: 31502 PMID: 27531070

Showing 10 of 18 publications

Added to your cart

View Cart Checkout
Loading...